Solara Active Pharma Sciences Ltd
Solara Active Pharma Reports Q2 FY27 Consolidated Net Profit of Rs. 28.46 Crores
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 16 Oct 2026, 01:38 PM IST · BSE ID: 11cf0245-5016-449a-8cda-fc51633bf1c4
View Original BSE Filing (PDF)
💡
In Simple Terms
The company released its latest quarterly financial report, showing Rs. 28.46 Crores in profit and Rs. 417.34 Crores in sales.
🤖 AI Summary
- Solara Active Pharma Sciences reported consolidated net profit of Rs. 28.46 Crores for Q2 FY27.
- Revenue from operations for the quarter ended September 30, 2026, was Rs. 417.34 Crores.
- Consolidated basic earnings per share for Q2 FY27 stood at Rs. 5.92 per share.
- The Board of Directors considered and approved the unaudited financial results on October 16, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
Rs. 417.34 Crores
Net Profit for the period (Q2 FY27)
Rs. 28.46 Crores
Revenue from operations (Q2 FY26)
Rs. 313.54 Crores
Net Profit for the period (Q2 FY26)
Rs. (10.10) Crores
Basic Earnings per equity share (Q2 FY27)
Rs. 5.92
🏢 How This Affects the Company
The company's consolidated net profit increased to Rs. 28.46 Crores in Q2 FY27 from a loss of Rs. 10.10 Crores in the corresponding period of the previous year, impacting earnings positively. Revenue from operations also increased to Rs. 417.34 Crores from Rs. 313.54 Crores YoY, indicating higher sales.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results disclosure.
👤
Who Is Affected
All equity shareholders are affected by the company's financial performance, with basic earnings per share reported at Rs. 5.92 for the quarter.
🔍
Management Signal
The approval of unaudited financial results indicates management's adherence to regulatory disclosure requirements and provides an update on the company's financial status.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — check for sustained profitability and revenue growth.
Management commentary — assess outlook on market conditions and business strategies.
Changes in cost of materials consumed — evaluate impact on future margins.
MEDIUM RISK
While profitability improved, managing significant cost of materials consumed and other expenses remains important.
💡 Investor Takeaway
Solara Active Pharma Sciences reported a Q2 FY27 consolidated net profit of Rs. 28.46 Crores, a significant improvement from a net loss of Rs. 10.10 Crores in Q2 FY26. Revenue from operations increased to Rs. 417.34 Crores, compared to Rs. 313.54 Crores in the previous year's corresponding quarter.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated net profit was Rs. 28.46 Crores for Q2 FY27, up from a loss of Rs. 10.10 Crores in Q2 FY26, indicating improved profitability.
- Revenue from operations grew to Rs. 417.34 Crores in Q2 FY27 from Rs. 313.54 Crores in Q2 FY26, reflecting increased sales.
📅 Company Track Record
Solara Active Pharma Sciences reported Q1 FY27 consolidated net profit of Rs. 16.31 Crores. In the same quarter of FY26, the company recorded a net profit of Rs. 28.46 Crores with revenue of Rs. 417.34 Crores. The company was incorporated in 2017.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Solara Active Pharma Sciences' consolidated net profit for Q2 FY27?
Solara Active Pharma Sciences reported a consolidated net profit of Rs. 28.46 Crores for the quarter ended September 30, 2026.
What was Solara Active Pharma Sciences' revenue from operations in Q2 FY27?
The company's revenue from operations for the quarter ended September 30, 2026, was Rs. 417.34 Crores.
How did Solara Active Pharma Sciences' Q2 FY27 profit compare to Q2 FY26?
The company's net profit for Q2 FY27 was Rs. 28.46 Crores, compared to a net loss of Rs. 10.10 Crores in the corresponding period of the previous year (Q2 FY26).
What were the basic earnings per share for Solara Active Pharma Sciences in Q2 FY27?
Basic earnings per equity share for Solara Active Pharma Sciences for Q2 FY27 (not annualised) stood at Rs. 5.92.
When were the Q2 FY27 financial results for Solara Active Pharma Sciences approved?
The unaudited financial results for the quarter and half year ended September 30, 2026, were approved by the Board of Directors on October 16, 2026.
Questions based on this BSE filing only. For information purposes.